However, data available from large clinical trials indicate that changes of amyloid-β signal were not associated with changes of disease clinical severity in patients with AD [19,41] and, to date, should not be used as a surrogate marker for efficacy.
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}